Acorda Builds on Ampyra Sales; Gains Option to Buy Neuronex
By Marie Powers
Friday, February 17, 2012
Boosted by 2011 net revenues of $210.5 million in the U.S., including fourth-quarter net revenues of $57.2 million, thanks to sales of Ampyra (dalfampridine) extended-release tablets, Acorda Therapeutics Inc. said Thursday it inked a deal to acquire privately held Neuronex Inc., which is developing a nasal spray formulation of diazepam for certain epilepsy patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.